It is not known if compounded semaglutide will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people
Semaglutide and other GLP-1 medications are typically considered for individuals who: As with any medication, the effect of GLP-1 medication varies from patient to patient
The National Institute for Health and Care Excellence (NICE) guideline NG28 recommends GLP-1 receptor agonists as part of type 2 diabetes management pathways, with treatment decisions based on glycaemic control, weight, and cardiovascular risk factors rather than autoimmune status
These symptoms could include mood swings, bloating, or changes in appetite, further indicating the drug's impact on your menstrual cycle
This usually resolves as the body adjusts to GLP-1-only activation
Maintain a regular exercise routine